Solventum Corp (SOLV)
Sous-évaluéFondamental
64
Prix
$87.41
Capitalisation boursière
$15.24B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$8.31B
12 derniers mois (au 30/06/2026)
Résultat net
$1.43B
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$-10M
Capitaux propres totaux
$5.05B
Passif total
$9.24B
Ratio de liquidité général
1.02
Couverture des intérêts
-
Dette/EBITDA
1.98
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$126.13
Prix actuel
$87.41
Marge de sécurité
+30.7%
Fourchette de juste valeur
$81.98 - $170.27
Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
10.76
ROE
30.8%
Ratio P/B
3.13
P/FCF
-
Marge brute
54.7%
ROIC
15.5%
Radar de rentabilité
Création de valeur (avantage concurrentiel)
ROIC
15.5%
WACC
6.3%
ROIC − WACC
+9.2 pp
Le ROIC dépasse le coût du capital — l'entreprise crée de la valeur pour les actionnaires.
Critères d'analyse fondamentale
Réussi (15)
- EPS shows upward trend
- Price CAGR 15.07%
- ROIC 15.5%
- Gross Margin 54.7%
- Debt/Equity ratio
- Operating Margin 25.0%
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 29.0%
- Analyst Consensus 59% Buy
- Earnings Surprise avg 11.0%
- Share Dilution 1.0%
- Net Margin Trend 17.3% vs 4.5%
- Piotroski F-Score 7/9
Échoué (7)
- EPS CAGR 4.51%
- P/B Ratio 3.13
- Positive Free Cash Flow
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Fairly valued)
- Earnings Quality (OCF/NI) 0.15
Indisponible (6)
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
Score F de Piotroski
Santé financière solide
Qualité des bénéfices
Qualité faible : examiner la comptabilité
Dilution du capital
Le nombre d'actions est stable
Participations institutionnelles
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Bryan C. Hanson | CEO & Director | 58 |
| Mr. Wayde D. McMillan | Executive VP & CFO | 55 |
| Ms. Amy Landucci | Chief Information & Digital Officer | 50 |
| Ms. Marcela A. Kirberger | Chief Corporate & Legal Affairs Officer & Corporate Secretary | 58 |
| Ms. Heather L. Knight | Chief Commercial Officer | 53 |
| Mr. Neil C. Zieselman | Senior VP, Controller & Chief Accounting Officer | 49 |
| Ms. Amy Wakeham | Senior Vice President of Investor Relations & External Finance Communications | - |
| Ms. Kate Dobbs | Chief Communications & Corporate Marketing Officer | - |
| Ms. Rachel H. Ellingson | Chief Strategy & Corporate Development Officer | 55 |
| Ms. Tammy L. Gomez | Chief Human Resources Officer | 52 |
Risque d'audit
10
Risque du conseil
3
Risque de rémunération
8
Risque droits des actionnaires
6
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Documents
- Voir le document
Rapport annuel (10-K)
Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.
Déposé le 2026-02-27
- Voir le document
Rapport trimestriel (10-Q)
Une mise à jour de la performance financière des trois derniers mois.
Déposé le 2026-08-05
- Voir le document
Rapport d'événement important (8-K)
Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.
Déposé le 2026-08-05
via SEC EDGAR
Historique des résultats
via SEC EDGAR
Latest News
Recent headlines for SOLV, sourced from Markets Gazette.
- 2/26/2026NEUTRALSolventum (SOLV) Q4 2025 Earnings Call Transcript
The transcript for Solventum Corporation's (SOLV) fourth-quarter 2025 earnings call has been made available, marking a routine event in the company's financial calendar. Solventum, a healthcare technology spin-off from 3M, is under investor scrutiny for its performance post-separation. While the release of the transcript is a standard step for transparency, the absence of the actual earnings content prevents an in-depth analysis. Investors are awaiting the detailed financial figures and future outlook to assess the business trajectory and potential implications for share value. Currently, the mere availability of the transcript, without the underlying data, provides no clear directional guidance for the market.
via Markets Gazette